Correction
Published on 20 Dec 2022
in Primary Immunodeficiencies
Original Research
Published on 16 Dec 2022
in Primary Immunodeficiencies
Original Research
Published on 14 Dec 2022
in Primary Immunodeficiencies
Review
Published on 09 Dec 2022
in Primary Immunodeficiencies
Case Report
Published on 09 Dec 2022
in Primary Immunodeficiencies
Review
Published on 08 Dec 2022
in Primary Immunodeficiencies
Case Report
Published on 08 Dec 2022
in Primary Immunodeficiencies
Editorial
Published on 02 Dec 2022
in Primary Immunodeficiencies
Case Report
Published on 01 Dec 2022
in Primary Immunodeficiencies
Mini Review
Published on 29 Nov 2022
in Primary Immunodeficiencies
Case Report
Published on 24 Nov 2022
in Primary Immunodeficiencies
Case Report
Published on 23 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 21 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 18 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 18 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 18 Nov 2022
in Primary Immunodeficiencies
Mini Review
Published on 17 Nov 2022
in Primary Immunodeficiencies
Case Report
Published on 17 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 03 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 02 Nov 2022
in Primary Immunodeficiencies
Original Research
Published on 28 Oct 2022
in Primary Immunodeficiencies
Original Research
Published on 25 Oct 2022
in Primary Immunodeficiencies
Case Report
Published on 24 Oct 2022
in Primary Immunodeficiencies
Case Report
Published on 21 Oct 2022
in Primary Immunodeficiencies
![Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies](https://www.frontiersin.org/files/myhome article library/1110388/1110388_Thumb_400.jpg)
